Clinical Trials Browser

Phase 2 × GSK2110183 × Clear all

NCT01532700 2019-09-24

An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed

28 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01531894 2019-07-09

Continuation Study of the Oral AKT Inhibitor GSK2110183

Phase 2 Completed

11 enrolled 8 charts

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT01445587 2012-03-26

A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

Phase 2 Withdrawn

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Neoplasms, Hematologic Neoplasms